) along with Nodality Inc. agreed for a strategic collaboration
under which they will utilize Nodality's proprietary Single Cell
Network Profiling (SCNP) technology to develop several of UCB's
compounds. The multi-year agreement will initially be focused on
Further, on the basis of information generated using Nodality's
technology, the agreement will give UCB the option to engage
Nodality in developing companion diagnostics for UCB's
Under the terms of the agreement, Nodality will receive an
upfront payment, R&D funding, and success-based payments on the
achievement of all applicable development, regulatory and
commercialization milestones. Nodality will also be eligible to
receive royalties on future diagnostic sales.
We note that this is the second collaboration that UCB has
entered into in less than a month. In early February, UCB and
Japanese pharmaceutical company Astellas Pharma Inc. announced a
collaboration to jointly develop and commercialize Cimzia
(certolizumab pegol) for rheumatoid arthritis (
) in Japan.
According to the agreement, UCB will manufacture and supply
Cimzia to Astellas for commercialization. Astellas will exclusively
distribute the drug and also book sales, while both Astellas and
UCB will jointly develop and commercialize Cimzia in Japan. Under
the agreement, UCB will receive an initial cash payment and is also
eligible to receive clinical, regulatory and commercial milestones
UCB and Astellas have filed Cimzia with the Japanese regulatory
authority, seeking approval of the drug for the treatment of RA in
patients who have responded insufficiently to current
Cimzia is currently marketed in the US and Europe for the
treatment of adults with moderate-to-severely active RA. The drug
is also marketed in the US for reducing signs and symptoms of
Crohn's disease (CD).
We currently have a Zacks #3 Rank (short-term Hold rating) on
To read this article on Zacks.com click here.